Knock‐in of the mutations using CRISPR/Cas9 gene editing recapitulated the phenotype resistance to AN3661 both in vitro and in the murine model of toxoplasmosis, thus validating CPSF3 as the primary target of AN3661. This evidence concerns the gene CPSF3 and toxoplasmosis.